Display Settings:

Format

Send to:

Choose Destination
Curr Opin Biotechnol. 2011 Dec;22(6):858-67. doi: 10.1016/j.copbio.2011.03.002. Epub 2011 Mar 21.

Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy.

Author information

  • 1Department of Chemical Engineering, University of Texas, Austin, TX 78712, United States.

Abstract

In recent years a number of aglycosylated therapeutic antibodies have entered the clinic. The clinical evaluation of these antibodies has served to dispel concerns that the absence of the ubiquitous N297 glycan in the Fc of IgG might result in immunogenicity, poor in vivo stability or unfavorable pharmacokinetics. Importantly, recent studies have now demonstrated that aglycosylated antibodies can be engineered to display novel effector functions and mechanisms of action that do not appear to be possible with their glycosylated counterparts. Moreover, the ability to manufacture aglycosylated antibodies in lower eukaryotes or in bacteria provides significant bioprocessing advantages in terms of shorter bioprocess development and running times and by completely bypassing the problems associated with the glycan heterogeneity of conventional antibodies. These advantages are poised to catapult aglycosylated antibodies to the forefront of protein therapeutics.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:
21420850
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk